|
Elliott, R.L., Stjernholm, Elliott, M.C.: Preliminary Evaluation of Platinum Transferrin (MPTC-63) as a Potential Nontoxic Treatment for Breast Cancer. Cancer Detection and Prevention 12:469-480, 1988.
Elliott, R.L., Page, M., and Head, J.F.: Further Evaluation of Platinum Transferrin (MPTC-63) and Daunorubicin Transferrin Conjugate as Potential Treatments for Breast Cancer (Possible Synergistic Response). Antibody Immunoconj. and Radiopharm 3:101, 1990.
Head, J.F., and Elliott, R.L.: Inhibition of Human Breast Carcinoma MCF-7 Growth by Gallium and Cisplatin Bound to Human Transferrin. Proc. Amer. Assoc. Cancer Res. 31:2440, 1990.
Elliott, R.L., Elliott, M.C., and Head, J.F.: Preliminary Results on 11 Advanced Breast Cancer Patients Treated with Cisplatin Complexed to Human Transferrin. Breast Cancer Res. Treat. 16:57, 1990.
Head, J.F., and Elliott, R.L.: Cisplatin-Transferrin Complex Acts Synergistically with Doxorubicin to Inhibit the Growth of Cultured MCF-7 Cells. International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 6:63, 1991.
Head, J.F., and Elliott, R.L.: Inhibition of MCF-7 and HeLa Cell Growth by Gallium-and Indium-Transferrin Complexes. Proc. Amer. Assoc. Cancer Res. 32:2298, 1991.
Head, J.F., and Elliott, R.L.: Inhibition of Cell Growth in Mammary Carcinoma Cell Lines by Deferoxamine Mesylate. Breast Cancer Res. Treat. 19:209, 1991.
Head, J.F., Bruce, T.L., and Elliott, R.L.: Inhibitory Effect of Deferoxamine Mesylate on the Growth of HeLa and MCF-7 Carcinoma Cell Lines. Proc. Amer. Assoc. Cancer Res. 33:505, 1992.
Elliott, R.L., Elliott, M.C., and Head, J.F.: Iron Metabolism in Breast Cancer (A Cytochemical, Tissue Culture, and Ultrastructural Study). Proc. Amer. Soc. Clin. Oncol. 11:62, 1992.
Elliott, R.L., Elliott, M.C., Wang, F., and Head, J.F.: Breast Carcinoma and the Role of Iron Metabolism: A Cytochemical, Tissue Culture, and Ultrastructural Study. Ann. New York Acad. Sci. 698:159-166, 1993.
Head, J.F., Wang, F., and Elliott, R.L.: Study of Iron Metabolism in Tumor Cells Suggests Novel Experimental Approaches to Cancer Chemotherapy. International Assoc. Breast Cancer Res., Biennial Meeting. A60, 1993.
Elliott, R.L., Elliott, M.C., Wang, F., and Head, J.F.: A Cytochemical, Tissue Culture and Ultrastructural Study: The Role of Iron Metabolism in Breast Carcinoma. International Assoc. Breast Cancer Res., Biennial Meeting. A61, 1993.
Wang, F., Head, J.F., and Elliott, R.L.: Deferoxamine Induced Ultrastructural Lesions of Nucleoli in MCF-7 Carcinoma Cell Line. Proc. 51st Annual Meeting of the Microscopy Society of America 51:198-199, 1993.
Wang, F., Hailey, M., Elliott, R.L., and Head, J.F.: Inhibitory Effect of Deferoxamine Mesylate on the Growth of Rat 13762NF Mammary Adenocarcinoma. Breast Cancer Res. Treat. 27:151, 1993.
Head, J.F., Nutt, D.R., Elliott, M.C., Wang, F., and Elliott, R.L.: Phase I/II Study of Sequentially Administered Deferoxamine, Cisplatin-transferrin Complex and FAC (5-fluorouracil, Doxorubicin, Cyclophosphamide) in Advanced Breast Cancer. Proc. Amer. Assoc. Cancer Res. 35:227, 1994.
Wang, F., Hailey, M., Ward, K., Elliott, R.L., and Head, J.F.: Growth Inhibition of Rat 13762NF Mammary Adenocarcinoma by Deferoxamine Mesylate. Proc. Amer. Assoc. Cancer Res. 35:406, 1994.
Elliott, R.L., Elliott, M.C., Wang, F., and Head, J.F.: The Role of Iron Metabolism in Metastatic Breast Carcinoma (Synergistic Action of Cisplatinum Transferrin Complex and Doxorubicin). Proc. Amer. Soc. Clin. Oncol. 13:80, 1994.
Head, J.F., Nutt, D.R., Elliott, M.C., and Elliott, R.L.: Phase I/II Trial in Advanced Breast Cancer Patients of Sequential Combination Chemotherapy with Deferoxamine, Cisplatin-Transferrin Complex and FAC (5-Fluorouracil, Doxorubicin, Cyclophosphamide). Annals of Oncology 5:169, 1994.
Elliott, R.L., Elliott, M.C., Wang, F., and Head, J.F.: Innovative Chemotherapy in Breast Cancer by Modulation of Transferrin Receptors: Transferrin as a Carrier of Cytotoxic Agents. Annals of Oncology 5:193, 1994.
Elliott, R.L., Nutt, D.R., Elliott, M.C., Head, J.F.: Clinical Study of Sequential Deferoxamine, Cisplatin or Gallium Transferrin Complex, and Cytotoxic Chemotherapy in Advanced Breast Cancer: International Congress on Anti-Cancer Chemotherapy 5:158, 1995.
Head, J.F., Wang, F., and Elliott, R.L.: Study of Iron Metabolism in Tumor Cells Suggests Novel Experimental Approaches to Cancer Chemotherapy: International Congress on Anti-Cancer Chemotherapy 5:159, 1995.
Wang, F., Head, J.F., and Elliott, R.L.: The up Regulation of Transferrin Receptors by Deferoxamine Enhances the Growth Inhibitory Effect of Gallium-Transferrin on MCF-7 Cells. Proc. Amer. Assoc. Cancer Res. 36:355, 1996.
Head, J.F., Wang, F., and Elliott, R.L.: Antineoplastic Drugs That Interfere With Iron Metabolism in Cancer Cells. Advan. Enzyme Regul. 37:147-169, 1997.
Wang, F., Jiang, X.P., Yang, D.C., Elliott, R.L., and Head, J.F.: Effects of Gallium and Gallium-Transferrin on DNA Synthesis, Ferritin Gene Expression and Cellular Ferritin Synthesis in MCF-7 Cells. Proc. Amer. Assoc. Cancer Res. 38:601, 1997.
Yang, D.C., Head, J.F., Wang, F., and Elliott, R.L.: Transferrin Receptor mRNA and Ferritin H-chain mRNA Expression are Associated with Prognostic Indicators for Breast Cancer. Proc. Amer. Cancer Res. 38:419-420, 1997.
Wang, F., Jiang, X.P., Yang, D.C., Elliott, R.L., and Head, J.F.: Doxorubicin-gallium-transferrin Conjugate Overcomes Multidrug Resistance: Evidence for Nuclear Drug Accumulation in Resistant Cells MCF-7/ADR. Breast Cancer Res. Treat. 46:236, 1997.
Jiang, X.P., Wang, F., Head, J.F., Yang, D.C., and Elliott, R.L.: The Deprivation of Iron Induces Apoptosis in MCF-7 Human Breast Cancer Cell Line and 13762NF Rat Mammary Adenocarcinoma Tumor. Breast Cancer Res. Treat. 46:468, 1997.
Yang, D.C., Head, J.F., Wang, F., Jiang, X.P., Ferris, J., and Elliott, R.L.: Growth Inhibition of Multidrug-sensitive and Multidrug-resistant Human Breast Cancer Cell Lines by Gallium-Transferrin. Proc. Amer. Cancer Res. 39:1760, 1998.
Yang, D.C., Head, J.F., Jiang, X.P., Wang, F., and Elliott, R.L.: Antisense Transferrin Receptor Oligonucleotide Suppresses Gene Expression and Proliferation in Human Breast Cancer Cell Lines. Proc. Amer. Assoc. Cancer Res. 39:2841, 1998.
Yang, D.C., Head, J.F., Jiang, X.P., and Elliott, R.L.: Reversal of Multidrug Resistance in the Human Breast Cancer MCF-7/ADR Cell Line by Gene-targeted Antisense Oligonucleotides. Breast Cancer Res. Treat. 50:360, 1998.
Head, J.F., and Elliott, R.L.: Determination of Tumor Ferritin Concentration in Breast Cancer. Meth. in Molecular Medicine 14:115-125, 1998.
Elliott, R.L., Suits, J.A., Yang, D.C., Jiang, X.P., and Head, J.F.: Increase in Serum Iron Concentration After Chemotherapy for Breast Cancer. Proc. Amer. Soc. Clin. Oncol. 18:805, 1999.
Yang, D.C., Elliott, R.L., Jiang, X.P., and Head, J.F.: Antisense-transferrin Receptor Gene Inhibits Growth of Breast Tumor Cells. Breast Cancer Res. Treat. 57:180, 1999.
Yang, D.C., Head, J.F., Jiang, X.P., and Elliott, R.L.: Liposome Mediated Antisense Ferritin Light Chain Transfection Inhibits Proliferation of Human Breast Cancer Cells. Proc. Amer. Assoc. Cancer Res. 40:3160, 1999.
Yang, D.C., Jiang, X.P., Elliott, R.L., and Head, J.F.: Reversal of Doxorubicin Resistance by Doxorubicin-Gallium-Transferrin Conjugate in Human Breast Cancer Cell Lines. Proc. Amer. Cancer Res. 40:4377, 1999.
Wang, F., Elliott, R.L., and Head, J.F.: Inhibitory Effect of Deferoxamine Mesylate and Low Iron Diet on the 13762NF Rat Mammary Adenocarcinoma. Anticancer Res. 19:445-450, 1999.
Yang, D.C., Jiang, X.P., Elliott, R.L., and Head, J.F.: Synergistic Inhibition of Breast Tumor MCF-7 Cell Growth by Combinations of Transferrin Receptor Antisense DNA, Deferoxamine and Hydroxyurea. Proc. Amer. Assoc. Cancer Res. 41:4091, 2000.
Yang, D.C., Jiang, X.P., Elliott, R.L., and Head, J.F.: Antisense Transferrin Receptor Oligonucleotide Induces Apoptosis in Human MCF-7 Breast Carcinoma Cells. Proc. Amer. Assoc. Cancer Res. 41:4781, 2000.
Wang, F., Jiang, X.P., Yang, D.C., Elliott, R.L., and Head, J.F.: Doxorubicin-gallium-transferrin Conjugate Overcomes Multidrug Resistance: Evidence for Drug Accumulation In the Nucleus of Drug Resistant MCF-7/ADR Cells. Anticancer Res. 20:799-808, 2000.
Head, J.F., Bruce, T.L., Wang, F., and Elliott, R.L.: Gallium Loaded Transferrin as a Specific Carrier of Paclitaxel into Breast Cancer Cells. Proc. Amer. Assoc. Cancer Res. 42:2019, 2001.
Yang, D.C., Jiang, X.P., Elliott, R.L., and Head, J.F.: Synergistic Inhibition of Breast Carcinoma Cell Growth by Combinations of HER-2/neu Antisense DNA and Chemotherapeutic Agents. Proc. Amer. Assoc. Cancer Res. 42:3915, 2001.
Yang, D.C., Head, J.F., Hanks, C., Jiang, X., and Elliott, R.L.: Her-2/neu Messenger RNA Expression in Human Breast Tumors Has Prognostic Significance. Proc. Amer. Soc. Clin. Oncol. 20:2626, 2001.
Yang, D.C., Wang, F., Elliott, R.L., and Head, J.F.: Expression of Transferrin Receptor and Ferritin H-chain mRNA are Associated with Clinical and Histopathological Prognostic Indicators in Breast Cancer. Anticancer Res. 21:541-549, 2001.
Yang, D.C., Jiang, X.P., Elliott, R.L., and Head, J.F.: Inhibition of Growth of Human Breast Carcinoma Cells by an Antisense Oligonucleotide Targeted to the Transferrin Receptor Gene. Anticancer Res. 21:1777-1787, 2001.
Jiang, X.P., Head, J.F., and Elliott, R.L.: Targeting of Transferrin Receptor with a Transferrin Receptor Antibody-doxorubicin-loaded Liposome Suppresses the Proliferation of MCF-7 Breast Cancer Cells. Proc. Amer. Assoc. Cancer Res. 43:2065, 2002.
Jiang, X.P., Head, J.F., and Elliott, R.L.: Targeting of HER2 with Herceptin-doxorubicin-loaded Liposome Suppresses the Proliferation of MCF-7 Breast Cancer Cells. Proc. Amer. Soc. Clin. Oncol. 21:1834, 2002.
Yang, D.C., McCreary, M.S., Jiang, X.P., Elliott, R.L., and Head, J.F.: Inhibition of Human Breast Cancer Cell Growth by a Plasmid that Expresses Her-2/neu Antisense RNA. Proc. Amer. Assoc. Cancer Res. 43:439, 2002.
Yang, D.C., Elliott, R.L., and Head, J.F.: Gene Targets of Antisense Therapies in Breast Cancer. Expert Opin. Ther. Targets 6:375-385, 2002.
Jiang, X., Elliott, R.L., and Head, J.F.: Targeting of Cancer Antigen 15-3 (CA 15-3) with a CA 15-3 Antibody-doxorubicin-loaded Liposome Complex Increases Doxorubicin Cytotoxicity Against the MCF-7 Human Breast Cancer Cells. Proc. Amer. Assoc. Cancer Res. 44:3663, 2003.
Jiang, X., Hsu, K., Denicola, D., Head, J.F., and Elliott, R.L.: Iron Protects MCF-7 Breast Cancer Cells from the Cytotoxic Effect of Nitric Oxide. Proc. Amer. Assoc. Cancer Res. 44:5024, 2003.
Jiang, X., Hsu, K., Denicola, D., Head, J.F., and Elliott, R.L.: Iron Impairs Natural Killer Cell Function. Proc. Amer. Assoc. Cancer Res. 44:3663, 2003.
Jiang, X., Hsu, K., Meseyton, D., Denicola, D., Elliott, R.L., and Head, J.F.: Doxorubicin-gallium-transferrin and Cisplatin-transferrin Conjugates Reverse Hypoxia-induced Drug Resistance in Breast Cancer MCF-7 Cells. Proc. Amer. Assoc. Cancer Res. 45:2142, 2004.
Jiang, X.P., Hsu, K., Head, J .F., and Elliott, R.L.: Effects of Iron on the Cytotoxicity of Nitric Oxide and the Associated Cytolysis by Natural Killer Cells of MCF-7 Human Breast Cancer Cells. Proc. Amer. Assoc. Cancer Res. 46:2433, 2005.
|
